Evofem Biosciences, Inc.EVFMOTCMARKET
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -12.05% | +46.81% | -76.55% | +15.99% | +10.14% |
| Gross Profit Growth | +15.69% | +43.94% | -83.56% | +20.02% | +9.37% |
| EBITDA Growth | -103.13% | +0.00% | +0.00% | -179.66% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -103.58% | +0.00% | +0.00% | -232.05% | +0.00% |
| EPS Growth | -100.15% | +0.00% | +0.00% | -178.97% | +0.00% |
| EPS Diluted Growth | -125.20% | +0.00% | +0.00% | -2025.00% | +0.00% |
| Weighted Average Shares Growth | +2176.87% | +435.57% | +19420.08% | +73.25% | +23.97% |
| Weighted Average Shares Diluted Growth | -86.79% | +0.00% | +19262.13% | +73.25% | +23.97% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +355.28% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +413.76% | +0.00% | +0.00% |
| Receivables Growth | -14.69% | +71.35% | -73.32% | +6.87% | -17.76% |
| Inventory Growth | -42.08% | -7.07% | +73.28% | +79.81% | +15.11% |
| Asset Growth | +79.72% | +125.40% | +56.71% | +68.19% | -42.33% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +8.64% | +5.98% | +7.81% | +9.02% | +44.76% |
| R&D Expense Growth | -42.46% | -53.07% | +747.64% | +176.30% | +41.57% |
| SG&A Expenses Growth | -11.06% | -4.32% | -3.93% | -0.93% | -17.57% |